My watch list
my.bionity.com  
Login  

03-18-2008: SemBioSys Genetics Inc. announced that it has been granted European patent EP0986309(B1) entitled "Uses of Oil Bodies". The patent has been issued to SemBioSys, which has exclusively licensed commercial rights associated with the patent to Botaneco Specialty Ingredients Inc., its wholly owned subsidiary. The claims of European Patent EP0986309(B1) are broadly directed to the production of emulsions comprising oleosomes extracted from any living cell, including plants such as safflower, and the use of these emulsions in a wide range of commercial applications including food ingredient, personal care and over-the-counter as well as pharmaceutical applications.

"This patent demonstrates our commitment to diligently protect our proprietary oleosome technology. It provides broad coverage for the production of personal care, topical OTC and pharmaceutical, food and other products based on emulsions comprised of oleosomes in the European market," said Andrew Baum, President and CEO of SemBioSys. "The issuance of this patent further validates our leadership in the use of oilbodies in personal care and other topical applications. We plan to launch Hydresia(TM), Botaneco's first oleosome based ingredient, in Europe this spring after a successful launch in the U.S. and Canada last year."

Counterparts to the European patent EP0986309(B1) have issued in many jurisdictions worldwide including the United States, Canada, Australia, Japan, China, India and Mexico.

Watchlist

This is where you can add this news to your personal favourites

Facts, background information, dossiers
  • SemBioSys Genetics
  • Japan
  • food ingredients
More about SemBioSys Genetics
  • News

    SemBioSys announces senior management change

    SemBioSys Genetics Inc. announced that effective March 25, 2010, Professor Maurice Moloney, Ph.D., the Company's Founder and Chief Scientific Officer has accepted a full-time position with the Biotechnology and Biological Sciences Research Council (BBSRC) and the Lawes Trust in the United K ... more

    SemBioSys begins phase I/II trial of insulin produced in plant seeds

    SemBioSys Genetics Inc. announced that it has initiated a phase I/II clinical trial of its plant-produced insulin with the first injection of its drug in humans. The trial, taking place in the United Kingdom (UK), will include up to 30 healthy volunteers in a three-arm study (SBS-1000 insul ... more

    SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office

    SemBioSys Genetics Inc. announced that it has been granted European patent EP0986309(B1) entitled "Uses of Oil Bodies". The patent has been issued to SemBioSys, which has exclusively licensed commercial rights associated with the patent to Botaneco Specialty Ingredients Inc., its wholly own ... more

  • Companies

    SemBioSys Genetics Inc.

    Calgary, Alberta-based SemBioSys is focused on leveraging its unique proprietary platform to manufacture high-value proteins and oils. SemBioSys’ seed-based protein production system can provide for its partners product enablement, exceptionally low cost and unprecedented scalability. SemBi ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE